Browsing: Nordisk

Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its weight-loss drug advertising

Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker’s lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy…

Novo Nordisk President and CEO Mike Doustdar discusses the company’s collaboration with artificial intelligence to accelerate drug discovery and development

Giann Liguid is a graduate of Ateneo De Manila University with an AB in Interdisciplinary Studies. With a diverse writing background, Giann has written content for the security, food and business industries. He also has expertise in both the public and private sectors, having worked in the government specializing in local government units and administrative…

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns…

For Novo Nordisk Philippines general manager Wei Sun, health isn’t a race to be won fast. It’s a lifelong partnership built on commitment and understanding

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets

Novo Nordisk A/SNVOreported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins

Novo Nordisk A/S (NOVO) held its Q2 2026 earnings call on August 5, 2026, during which the Phase III failure of ziltivekimab in cardiovascular outcomes dominated the R&D discussion, , while management defended CagriSema’s competitive positioning versus tirzepatide and the outlined the next wave of obesity assets led by zenagamtide

The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reaction underscored how sensitive investors are to clinical data, pipeline clarity, and competitive pressure from Eli Lilly’s obesity drugs. For you, this creates a chance to reassess exposure to companies tied…